Vutrisiran Reduces Neurologic Damage, Improves Physical Function, Trial Data Show

Vutrisiran Reduces Neurologic Damage, Improves Physical Function, Trial Data Show

282618

Vutrisiran Reduces Neurologic Damage, Improves Physical Function, Trial Data Show

Vutrisiran, a second-generation RNA interference (RNAi) therapy candidate, safely and effectively reduces neurologic impairment and improves physical function and quality of life in adults with familial amyloid polyneuropathy (FAP). That’s according to top-line, nine-month data from the global HELIOS-A Phase 3 trial. Alnylam Pharmaceuticals, Vutrisiran’s developer, plans to present the trial’s full results at a medical meeting in the upcoming months and to announce additional 18-month data by late 2021. “The HELIOS-A results reinforce our…

You must be logged in to read/download the full post.